Personalizing bipolar disorder treatment

April 22, 2015, Tel Aviv University
Personalizing bipolar disorder treatment

Rapidly swinging from extremes of joy and energy to sadness, fatigue, and confusion, bipolar disorder (BD) patients feel desperate and largely alone in the world. And according to the National Institutes of Health, between 25-50 percent of the roughly 3% of Americans living with BD attempt suicide at least once. Lithium is among the most effective therapies for BD, and remains the first-line treatment even as other mood stabilizing drugs have become available. But about half of the patients prescribed lithium do not respond to the treatment.

A new Tel Aviv University study, published in the Journal of Molecular Neuroscience, may pave the way for improving the efficacy of lithium in these . The study found that the insulin-like growth factor 1 (IGF-1) hormone, known for its pivotal role in tissue growth, is also capable of increasing the lithium sensitivity of in bipolar disorder patients in whom lithium was originally ineffective.

The research was led by TAU postgraduate student Dr. Elena Milanesi under the guidance of Dr. David Gurwitz of the Department of Human Molecular Genetics and Biochemistry of TAU's Sackler Faculty of Medicine and Sagol School of Neuroscience and Dr. Noam Shomron of the Department of Cell and Developmental Biology at TAU's Sackler Faculty of Medicine, in collaboration with Sackler graduate student Adva Hadar and Prof. Haim Werner of TAU's Sackler Faculty of Medicine, along with researchers in Italy and Germany.

A new hope

"Lithium has been considered the cornerstone in the management of bipolar disorder for over 50 years, even though half of patients do not sufficiently respond to chronic lithium treatment," said Dr. Gurwitz. "It is often prescribed as the first-line treatment for bipolar disorder. If it works, patients take it for years. If not, they have to explore alternatives which haven't proven as effective in long-term clinical studies."

The researchers examined the in vitro effects of insulin-like growth factor 1 (IGF-1) on lithium sensitivity in blood cell lines of both lithium-responsive and non-responsive bipolar patients. They found that when IGF-1 was added to the cultured blood cells there was increased lithium sensitivity only in the blood cells of those bipolar disorder patients who did not respond to lithium therapy.

"Our study suggests that the lack of sufficient IGF-1 activity may underlie lithium resistance in the treatment of bipolar disorder, and this hormone, or drugs mimicking or promoting its action, should be considered for improved treatment of this disorder", says Dr. Milanesi.

"There are no established animal models for bipolar disorder, so it will be hard to test this idea in animals," Dr. Gurwitz added. "However, given that IGF-1 is approved for human use in people who are deficient in this hormone, a clinical trial of IGF-1 in lithium-resistant patients is warranted."

The research on resistance biomarkers was supported by the U.S.-Israel Binational Science Foundation (BSF).

Explore further: Two SNPs predict lithium response in bipolar I disorder

Related Stories

Two SNPs predict lithium response in bipolar I disorder

December 31, 2013
(HealthDay)—For patients with bipolar I disorder, two single nucleotide polymorphisms (SNPs) in glutamate decarboxylase-like protein 1 (GADL1) predict response to lithium, according to a study published online Dec. 25 in ...

The hunt for a successor to lithium for bipolar disorder

March 27, 2013
Toxicity problems and adverse side effects when taking lithium, the mainstay medication for treating bipolar disorder, are fostering a scientific hunt for insights into exactly how lithium works in the body—with an eye ...

Body clocks may hold key for treatment of bipolar disorder

March 13, 2012
Scientists have gained insight into why lithium salts are effective at treating bipolar disorder in what could lead to more targeted therapies with fewer side-effects.

Lithium reduces risk of suicide in people with mood disorders

June 28, 2013
The authors say the drug "seems to reduce the risk of death and suicide by more than 60% compared with placebo" and suggest this review "reinforces lithium as an effective agent to reduce the risk of suicide in people with ...

Giving lithium to those who need it

September 21, 2012
Lithium is a 'gold standard' drug for treating bipolar disorder, however not everyone responds in the same way. New research published in BioMed Central's open access journal Biology of Mood & Anxiety Disorders finds that ...

Recommended for you

Infants are able to learn abstract rules visually

February 22, 2018
Three-month-old babies cannot sit up or roll over, yet they are already capable of learning patterns from simply looking at the world around them, according to a recent Northwestern University study published in PLOS One.

Color of judo uniform has no effect on winning

February 22, 2018
New research on competitive judo data finds a winning bias for the athlete who is first called, regardless of the colour of their uniform. This unique study, published in Frontiers in Psychology, puts to rest the debate on ...

Antidepressants are more effective than placebo at treating acute depression in adults, concludes study

February 22, 2018
Meta-analysis of 522 trials includes the largest amount of unpublished data to date, and finds that antidepressants are more effective than placebo for short-term treatment of acute depression in adults.

Smartphones are bad for some teens, not all

February 21, 2018
Is the next generation better or worse off because of smartphones? The answer is complex and research shows it largely depends on their lives offline.

How people cope with difficult life events fuels development of wisdom, study finds

February 21, 2018
How a person responds to a difficult life event such as a death or divorce helps shape the development of their wisdom over time, a new study from Oregon State University suggests.

Researchers uncover novel mechanism behind schizophrenia

February 21, 2018
An international team of researchers led by a Case Western Reserve University School of Medicine scientist has uncovered a novel mechanism in which a protein—neuregulin 3—controls how key neurotransmitters are released ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.